Subcutaneous (SC) delivery has become the norm for treating diseases such as Rheumatoid arthritis and multiple sclerosis, and there remains great potential to offer home- or even self-administered SC delivery for several other biotherapeutics. Given that there are a number of products already on the market, they can be examined to understand what improvements and changes can be made to increase product development opportunities and also enhance the patient experience.

In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, you will hear from clinicians (pharmacist and physician) and industry to gain insight into needs and preferences of future SC biotherapeutic formulations and devices. For example, panelists will address the issue of reducing costs and dose complexity, improving adherence, and also provide input on changes they would like to see in future SC biotherapeutic products.

Moderated by: Dr Beate Bittner, Roche

Panelists include:

Dr Mary Nauffal, Brigham and Women's Hospital
Dr Manuel Sanchez-Felix, Novartis Institutes for BioMedical Research
Dr Anand Subramony, AstraZeneca
Dr David Ting, MGH Cancer Center/Harvard Medical School

To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

Formulation & Device Lifecycle Management for Biotherapeutics

Share

Embed